• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-naïve patients and in the post-docetaxel ...
Source: Therapeutic Advances in Urology - July 16, 2015 Category: Urology & Nephrology Authors: Gartrell, B. A., Saad, F. Tags: Reviews Source Type: research

Navigating the Treatment Landscape
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a...
Source: Kidney Cancer Association - December 3, 2014 Category: Urology & Nephrology Source Type: news

Navigating Treatment Decisions
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rs...
Source: Kidney Cancer Association - February 7, 2012 Category: Urology & Nephrology Source Type: news